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SUMMARY We are far away from the days when tuberculosis (TB) accounted for 1
in 4 deaths during the 19th century. However, Mycobacterium tuberculosis complex
(MTBC) strains are still the leading cause of morbidity and mortality by a single in-
fectious disease, with 9.6 million cases and 1.5 million deaths reported. One-third of
the world’s population is estimated by the WHO to be infected with latent TB. Dur-
ing the last decade, several studies have aimed to deﬁne the characteristics of dor-
mant bacteria in these latent infections. General features of the shift to a dormant
state encompass several phenotypic changes that reduce metabolic activity. This low
metabolic state is thought to increase the resistance of MTBC strains to host/envi-
ronmental stresses, including antibiotic action. Once the stress ceases (e.g., interrup-
tion of treatment), dormant cells can reactivate and cause symptomatic disease
again. Therefore, a proper understanding of dormancy could guide the rational de-
velopment of new treatment regimens that target dormant cells, reducing later re-
lapse. Here, we brieﬂy summarize the latest data on the genetics involved in the
regulation of dormancy and discuss new approaches to TB treatment.
KEYWORDS Mycobacterium tuberculosis, pretomanid, teixobactin, toxin-antitoxin,
bedaquiline, dormancy, lassomycin, latency, persistent
INTRODUCTION
Although treatment regimens for tuberculosis (TB) have evolved over the years,control of the disease is difﬁcult, and in 2015, active TB still accounted for 1.5
million deaths (1). According to the World Health Organization (1), current guidelines
for TB treatment consist of a 2-month period of four antibiotics, isoniazid (INH), rifampin
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(RIF), ethambutol (EMB), and pyrazinamide (PZA), followed by a 4-month period of INH
and RIF (1). The duration of this treatment challenges patient adherence and conse-
quently limits its overall effectiveness. Even more challenging is the therapy for
multidrug-resistant (MDR) TB cases, which are deﬁned as having resistance to RIF or
INH, and extensively drug resistant (XDR) TB cases, deﬁned as having MDR plus
resistance to at least one ﬂuoroquinolone and 1 second-line injectable drug (1, 2).
Treatment of infection by MDR/XDR strains requires 9 to 20 months or even longer, and
the rate of a successful outcome falls below 50% on a global level (1, 2). Overall, a
reduction in the duration of conventional and MDR/XDR treatment is considered a
prime objective in the development of future treatment regimens to better prevent
emerging resistance and increase the rate of successful treatment (3).
In 1958, it was proposed that the underlying reason for long treatment durations
was the presence of nonreplicating cells (4). These cells, during active infection,
represent a small subpopulation that remains unaffected during standard antibiotic
therapy, requiring the use of special drugs with sterilizing capacities, such as PZA and
RIF (5). Even if the patient completes treatment, dormant cells can resuscitate after
decades, leading to relapse, especially in immunocompromised patients or those with
coinfection with human immunodeﬁciency virus (HIV) or merely due to ageing (6).
The development of more-effective, shorter TB treatment requires not only the rapid
killing of actively dividing cells but also the effective elimination of dormant popula-
tions. Therefore, there is an urgent need to understand the cellular and molecular basis
of mycobacterial dormant states. How do cells enter the dormant state? What are their
vulnerable points in dormancy? How can these vulnerabilities be exploited as new drug
targets? This knowledge will allow the rational development of more-effective and
shorter TB treatment regimens (7). In this review, we present an overview of recent
ﬁndings describing the dormant phenotype in Mycobacterium tuberculosis complex
(MTBC) strains and potential therapeutic options to tackle this problem.
WHAT IS DORMANCY?
Dormancy is a reversible metabolic shutdown (8), deﬁned here for simplicity as a
reversible, nonreplicating cellular state that enables mycobacteria to circumvent and
survive host defenses (9). The earliest attempts to reproduce in vitro the nonreplicative
state of MTBC cells began in 1994, resulting in the so-called Wayne model, which relies
on the observation that a two-phase reduction of O2 availability leads MTBC cells to a
nonreplicating state (10). Since then, similar models have been studied further, and it
is now commonly accepted that virtually any kind of nutrient restriction causes a
reduction in metabolic activity and subsequent dormancy (6). However, the mecha-
nisms involved in this reduced metabolism that protects bacteria against most anti-
mycobacterial drugs remain unclear.
Most antibiotics interfere with processes that are vital for actively dividing micro-
organisms, such as DNA replication, translation, or cell wall formation. An interruption
of any of these processes, an imbalance between cellular processes, or the creation of
metabolic products for which the cells cannot compensate leads to either a halt in
replication (bacteriostatic drugs) or cell death (bactericidal drugs). As most drug targets
are essential to replicating cells only, a reduction in metabolic activity protects the cell.
This is frequently the cause of a decrease in drug efﬁcacy and hence a reduction or
disappearance of the drug’s killing effect. Critically, this protective effect from the
metabolic state is general, applying to many antibiotics from different classes simulta-
neously (8).
If a given treatment fails to kill even a small proportion of bacteria, there is the
potential for resuscitation and consequent relapse, even years after treatment comple-
tion (Fig. 1). This nongrowing or low-replicating state can be considered a critical
component of the MTBC life cycle, allowing long-term survival in the host. Intriguingly,
it has been proposed that this nonreplicating state is decisive for the success of MTBC
strains, and it can be achieved by a number of different mechanisms.
Caño-Muñiz et al. Clinical Microbiology Reviews
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Entry into dormancy can be an active process in which speciﬁc signals trigger the
activation of master regulatory genes to drive MTBC cells toward the low-replicating/
nonreplicating state. The Wayne model (nonreplication induced by hypoxia) contrib-
uted to the identiﬁcation of key genes related to in vivo dormancy (10). The principal
transcription factor in this model is the regulator DosR (also DevR), which is activated
in response to hypoxia as well as nitric oxide produced by macrophages (11). DosR
directly modulates the expression of at least 48 genes, enabling MTBC cells to survive
during hypoxia (12). This model was also used to identify the essential gene phoP,
which mediates the early hypoxic response and participates in MTBC virulence (13).
Similar pathways based on amino acid starvation, carbon limitation, or virtually any
nutrient stress can also lead MTBC cells into dormancy. This transition of phenotype is
a result of the stringent response and is orchestrated by the metabolite (p)ppGpp,
known as the alarmone signal, and polyphosphate (poly-P) (14, 15). The stringent
response begins when stress signals trigger the rapid synthesis of poly-P catalyzed by
polyphosphate kinase (PPK) (16) and simultaneously constrain poly-P degradation by
blocking exopolyphosphatase (PPX) (17). The accumulation of this molecule increases
the activity of the two-component transcription regulator MprA/MprB (16), which
subsequently enhances the expression of M. tuberculosis Rel (RelMtb), the enzyme that
synthesizes ppGpp, and sigma factor E (E). The latter is a subunit of RNA polymerase
that has a high afﬁnity for promoters of stress-resistant genes, favoring the phenotypic
shift to stress resistance.
The mycobacterial stringent response appears to be stabilized by two positive-
feedback loops (Fig. 2): ﬁrst, the transcription factor MprA regulates its operon posi-
tively, and second, as poly-P accumulates in the cell, it induces relMtb expression and
ppGpp synthesis, with ppGpp inhibiting PPX, which degrades poly-P (18).
Many reports have recently related the stringent response to dormancy, both as a
whole and as individual components. For example, it has been found that poly-P
contributes to antibiotic tolerance. Infection of guinea pigs with an MTBC Δppk2 strain,
with a deletion of the gene encoding the enzyme responsible for poly-P synthesis, led
to a reduction in persistence and higher antibiotic susceptibility (19) (20). In addition,
an MTBC strain lacking relMtb has been shown to be more vulnerable in vitro to nutrient
deprivation and hypoxia (15), also resulting in a decreased ability of this strain to
sustain chronic infection in mice (21) and in guinea pig lungs (22). Finally, E is
upregulated when the bacterium grows within human macrophages, and its deletion
leads to attenuated viability (23).
FIG 1 Progression of tuberculosis. Here we consider symptomatic disease the beginning of the disease.
During infection, MTBC bacteria (red dots) actively colonize different areas of the lungs. During this
phase, most cells are actively growing. Thus, they are potentially susceptible to treatment and the
immune response. Macrophages (blue cells) phagocytose MTBC cells, but dormant cells are better able
to survive inside macrophages. T cells (light green), B cells (dark green), and giant foam cells (orange)
contain the infection in a structure called a granuloma. Thus, there are three possible outcomes after
treatment starts: interruption or failure of treatment that leads to a relapse where MTBC bacteria break
the barrier of the granuloma, reactivating infection (A); partially effective treatment that leads to a stable
quiescent structure with contained viable cells, which persist after treatment stops (B); or eradication of
the disease (MTBC cells are entirely removed from the healing granuloma) (C).
Therapy for M. tuberculosis in a Dormant State Clinical Microbiology Reviews
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The stringent-response hypothesis, therefore, may partly explain how cells enter
into the dormant state once they sense stress in their environment, yet it does not
clarify the nongrowing populations previous to any stress. A complementary hypoth-
esis proposed by Balaban and colleagues suggests that pathogens can display a
nongrowing phenotype, even in the absence of environmental stress as a phenotypic
switch (24). This might involve the stochastic activation of a molecular mechanism that
allows random switching between growing and nongrowing phenotypes. This phe-
nomenon is known as persistence. In contrast to dormancy, persistence involves a
preexisting subpopulation, deﬁned here as a nongrowing fraction of the bacterial
population, which displays a nonheritable ability to survive exposure to high concen-
trations of an antibiotic (24).
Although the nongrowth strategy could seem counterproductive for bacteria, Kus-
sell and colleagues have shown that a stochastic switch between growing and non-
growing (persister) phenotypes can be an evolutionarily favorable strategy (25). Their
model states that even during optimal growth (before sensing stress), there is a small
fraction of the population in a nongrowing state (25, 26). These dormant cells act as an
“insurance policy” against unpredictable risks, protecting the population as a whole
(26). Incidentally, the fraction of persistent cells directly affects the growth rate, with a
larger persistent fraction resulting in less growth. This fact could partially explain why
MTBC cells grow slowly in vitro, even in rich growth medium (27). The immediate
question that emerges here is what is the mechanism that MTBC cells use to “ignore”
the external conditions to maintain or trigger persistence.
Toxin-Antitoxin in M. tuberculosis Complex Strains
In the last decades, it has been proposed that toxin-antitoxin (TA) modules can
control the stochastic switch between growing and nongrowing phenotypes (8). TA
modules comprise two or more genes in the same operon (Fig. 3A): one has a “toxic”
effect that leads to the dormant phenotype, and the other is an antitoxin that
counteracts this effect to allow cell growth (8). The most common regulatory circuit of
TA modules (TA type II) is based on two elements: a positive-feedback loop, where the
toxin induces its expression, and the fragility of the antitoxin. In combination, this
creates a stochastic equilibrium, which means that switching between the “growing”
and “nongrowing” phenotypes is controlled partially by environmental signals and
partially by random stochastic factors (26, 28). As a consequence, regardless of the
external conditions, this mechanism generates a heterogeneous population in which
most cells are actively dividing, but some are in a persistent state. This phenomenon is
probably one of the main reasons why the eradication of MTBC bacteria in the host is
FIG 2 Representation of the partial regulatory network of the MTBC stringent response. Stress signals trigger poly-P
accumulation, activating the two-component Mpr complex. This increases SigE expression, which, in conjunction with the
Mpr complex, activates the transcription of relMtb, thereby increasing the concentration of ppGpp. In a positive-feedback
loop, ppGpp in turn blocks PPX activity, amplifying the signal and triggering the stringent response.
Caño-Muñiz et al. Clinical Microbiology Reviews
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so complicated. Remarkably, it has been determined that the MTBC has around 80 TA
modules, while its nonpathogenic relatives Mycobacterium smegmatis and M. marinum
have only 4 and 1 TA modules, respectively (28).
To date, ﬁve TA families have been described, based on the mode of inhibition of
the toxin. However, only TA type II has been reported to be present in MTBC strains (29).
The type II TA modules are characterized by a speciﬁc mode of action where the
antitoxin inhibits the toxin that would otherwise block protein translation (28), al-
though this can be achieved by a different mechanism depending on the TA family (Fig.
3B). This halt in protein synthesis stops cell growth. Interestingly, the latest research
indicated that the protein synthesis block is not random; it is instead part of a coherent
response for establishing the dormant phenotype (29–31).
The two largest TA families in the MTBC, VapBC and MazEF, cleave RNA (28). VapBC,
with more than 50 copies in MTBC strains, cleaves tRNA, causing a halt in protein
translation (32). Several VapBC modules were found to be upregulated in a nutrient
starvation model, and VapBC modules were found to be induced by stimuli present
during infection, such as hypoxia or interferon (IFN) (33). These facts directly connect
VapBC with the establishment of dormant infection. The MazEF toxin selectively cleaves
mRNA, which ultimately promotes a speciﬁc change in the transcriptome (30, 31). The
expression of toxins from the MazEF family has also been reported during infection of
macrophages and antibiotic treatment in vitro and for MTBC cells in infected mouse
lungs (34).
In addition, three other minor TA families have been identiﬁed in MTBC strains,
although they are not as thoroughly characterized as those described above. The RelBE
family is present in the MTBC in three copies: RelBE, RelFG, and RelJK (31) (35). The
overexpression of toxin genes of this family inhibits cell growth (35); however, the
deletion of individual cassettes does not affect virulence in a mouse model, suggesting
that these toxins may not individually contribute to virulence in vivo (36). The HigBA
family is among the 10 most upregulated TA systems in MTBC drug-tolerant persisters
(37). Finally, TAC (toxin-antitoxin-chaperone) seems to be induced in vitro under several
stress conditions, such as DNA damage or drug treatment (29).
FIG 3 Representation of TA functioning. (A) Typical structure of a TA operon. The toxin gene (T) produces
a protein that leads to dormancy; however, an antitoxin (A) that counteracts the toxin’s effects is also
encoded in the same mRNA. The cell enters into dormancy only when antitoxin is degraded. (B)
Mechanism of action of the major TA families in the MTBC. (i) VapBC attacks tRNA, (ii) RelBE binds to the
ribosomal A site, and (iii) MazEF is an endonuclease that cleaves mRNA sequences.
Therapy for M. tuberculosis in a Dormant State Clinical Microbiology Reviews
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Altogether, these data support the idea that TA modules have a key role in persistence
(29). However, there are still open questions, such as the degrees of interaction between
different TA systems or the difference in TA regulation between MTBC lineages.
From Genotype to Dormant Phenotype
Novel approaches seek a systemic reconstruction of the MTBC regulatory network
during dormancy to predict changes in gene expression and cellular metabolic condi-
tions (38). While many genes, such as those involved in central carbon metabolism,
rRNA synthesis, and cell division, are downregulated during dormancy, other genes are
upregulated, actively contributing to the metabolic shift (Fig. 4).
The transition to dormancy is facilitated by Clp proteases. These proteases are
essential for MTBC viability, as they are responsible for the selective degradation of
misfolded proteins that accumulate under stress (39). For example, ClpX has been
shown to be upregulated during entry into dormancy induced by hypoxia (32). The
resulting proteome and transcriptome are characterized by the downregulation of the
glycolysis, DNA replication, and protein synthesis pathways (32, 33). However, energy
metabolism and ATP synthesis remain essential processes in dormant cells (40). The
maintenance of ATP production is achieved by an increase in Krebs cycle activity and
the upregulation of the isocitrate lyase (icl-1) of the glycolate shunt (41). Other changes
required to maintain ATP production during dormancy are the upregulation of NADH
dehydrogenase 2 (NDH-2), nitrate reductase (NarG-I), and nitrate transporter (NarK2)
complexes and the downregulation of the NDH-1 and cytochrome complexes (40).
Furthermore, dormant MTBC cells increase their cell wall thickness and, with it, fatty
acid metabolism. Indeed, lipid metabolism has been demonstrated to be crucial for
dormancy and subsequent reactivation. Genes such as mce4, related to cholesterol
transport, or the triacyl glycerol synthase (tgs) gene that participate in fatty biosynthesis
appear to be required for persistence (42). A tgs1 deletion mutant exhibited a lower
degree of antibiotic tolerance, and complementation restored antibiotic tolerance (41).
Interestingly, lipid body inclusions have been found to be a distinctive characteristic of
persistent bacilli in sputum (43). Finally, the structural gene acr (-crystallin) has been
demonstrated to be a key factor for dormancy and is currently being studied for its use
as a biomarker for latent MTBC infection (44).
Although it is not known if the genes and proteins identiﬁed through in vitro
models, such as those for hypoxia, starvation, or antibiotic-TA, correspond directly to
human disease, they represent very useful knowledge for further studies targeting this
process. Research using these models has demonstrated their utility for ﬁnding new
drug targets and understanding the basis of resistance.
FIG 4 Schematic description of the cooperative-dormancy model (A) versus the unique-dormancy model
(B). (A) It is possible that there is a single spectrum of dormant phenotypes with a network of different
signals triggering entry and exit from this dormant phenotype (pale red and green arrows). This could
happen through an interconnected system in which TA modules (red arrow) interact with the stringent
response (blue arrow), which results in a distinctive dormant phenotype (black cells). Dormant cells may
be resuscitated by resuscitation-promoting factor, nutrients (green arrow), the degradation of toxin
modules, or other signals (orange) stimulating cells to restart growth. (B) It is also possible that there is
only one growth phenotype and that, depending on the signal, cells switch by independent mechanisms
to separate dormant phenotypes. TA modules (red arrow) could generate one distinctive kind of dormant
cell, and these cells will resuscitate only when toxin modules are removed from the cell (green arrows).
Growing cells could respond to environmental signals through the stringent response (blue arrow) to
enter a distinct form of dormancy. These cells will resuscitate when the appropriate stimulus, for
example, resuscitation-promoting factor, or nutrients (orange arrow) are present.
Caño-Muñiz et al. Clinical Microbiology Reviews
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STRATEGIES TO TARGET DORMANT CELLS
The design of new treatments targeting persistent populations in mycobacteria
appears to be critical for the development of more-effective and shorter TB therapies.
Currently, the four-drug standard treatment contains only one drug (PZA) that targets
explicitly dormant cells, while the others act mainly on growing cells (5).
The replacement of streptomycin by PZA in combination with RIF shortened TB
treatment from 12 to 6 months (short-course regimen) while keeping relapse rates low.
Although this was thought to be due to the extraordinary capacity of PZA to kill
dormant cells, the precise mechanism of action of pyrazinoic acid (the active form of
PZA) is not fully understood. The conventional model proposed that a low pH was
required for PZA activity, but this has recently been questioned (45). It was also
proposed that PZA targets fatty acid synthase I (FAS-I), but a lack of correlation between
FAS-I activity and the PZA dosage has stimulated the search for an alternative model
(46). New insights proposed a double mechanism: PZA depletes coenzyme A (CoA)
reservoirs and blocks the production of phthiocerol dimycocerosate (a virulence factor).
This CoA pathway seems to be essential only in dormant cells (47), which might explain
why PZA has greater sterilizing power on slower-growing cells. Another plausible
mechanism of action for PZA may be its ability to bind the ribosomal protein S1 (RpsA),
which halts protein translation (48).
Unfortunately, PZA is a prodrug. Thus, mutations in the gene responsible for PZA
activation, the pyrazinamidase gene (pncA), represent a major cause of bacterial
resistance to PZA. This is an emerging problem (49) that is rendering short-course
treatment more difﬁcult.
Taking into account all of the above-described data, novel approaches and new
drugs targeting essential processes in dormant cells would be expected to be very
efﬁcient in shortening treatment. Here, we have categorized these approaches into two
groups: (i) new drugs against dormant MTBC cells and (ii) alternative treatment
concepts.
New Drugs Active against Dormant TB
Considering the global epidemic of drug-resistant strains, drug discovery and
development are priorities, yet they are proving to be difﬁcult and time-consuming
endeavors. Thirty-nine drugs are currently in development (50), but only six of them
aim to target cells in the dormant state (Table 1).
During the last decade, cyclopeptides emerged as a promising group of drug
candidates. Using an original technique to grow uncultivable microorganisms, the
Lewis group discovered lassomycin, which has potent speciﬁc activity against myco-
bacteria. The drug binds the protease ClpC1 without affecting related AAA ATPases. The
Clp proteases are essential in mycobacteria, so they are an excellent target to eradicate
nongrowing cells (39). When lassomycin interacts with ClpC proteases, it disrupts the
proteolytic activity of the complex, and cells are believed to die because of the
accumulation of misfolded proteins (51). In vitro assays showed that lassomycin has
great killing activity against both exponentially growing cells and stationary-phase
starved cells (51). Another cyclopeptide family, the acyldepsipeptides (ADEPs), shows a
high efﬁcacy of killing activity against persistent subpopulations in MTBC cultures, also
by interfering with native Clp activity. In contrast to lassomycin, this compound
TABLE 1 Antibiotics described in this review
Antibiotic Phase Target Reference(s)
Lassomycin Preclinical ClpP 45–47
ADEP4 Preclinical ClpP 48, 49
Aurachin RE Preclinical Energy metabolism 50
Teixobactin Preclinical Cell wall 52
CPZEN-45 Phase I Cell wall 54, 55
Pretomanid Phase II 56
Bedaquiline Phase III Energy metabolism 57, 58
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increases the activity of ClpP1 in MTBC strains (52) and kills pathogens through the
nonspeciﬁc degradation of over 400 proteins. When combined with RIF, this compound
is capable of eradicating persistent subpopulations in either exponential- or stationary-
phase cultures (53). Finally, a very promising compound in the preclinical stage is
teixobactin (54). This molecule is a macrocyclic depsipeptide and targets lipid II and
lipid III, which are precursors of the cell wall (55). Once the antibiotic binds to the lipids,
it inhibits the maturation of the peptidoglycan layer, leading to cell lysis. As of today,
it is not understood why this mechanism eradicates persistent populations, but the
original study illustrates that after in vitro treatment of MTBC cells with teixobactin, no
colonies were formed by aliquots plated onto fresh medium (54).
In phase I trials, only one compound exhibits activity against dormant MTBC
bacteria. CPZEN-45 is a capreomycin derivate, and early assays showed that it had
excellent activity against drug-sensitive strains as well as against nutrient-starved MTBC
bacteria (56). CPZEN-45 seems to act by the inhibition of the undecaprenyl-P-GlcNAc-
1-P transferase (WecA), which is responsible for the initiation of cell wall synthesis (57).
Nevertheless, many studies are required to understand the role of WecA in dormant
cells, and the exact mechanism that makes this compound effective against dormant
MTBC cells needs to be clariﬁed.
In a later stage of development, phase II, pretomanid (PA-824) represents a pro-
mising candidate with activity against both growing and nongrowing MTBC cells. When
the drug was tested on nongrowing cells induced by hypoxia, MTBC cells showed
susceptibility to micromolar concentrations of the drug. This might be because preto-
manid attacks energy metabolism, which is essential for MTBC strains (40), by directly
releasing NO and causing respiratory poisoning (58). However, pretomanid is a prodrug,
requiring intracellular modiﬁcations for its biological activation, and it has already been
found that a reduction in the level of glucose-6-phosphate dehydrogenase, or its
deazaﬂavin cofactor F420, makes strains resistant (59).
Finally, in phase III, TMC207 or bedaquiline represents both a novel chemical class
(diarylquinolines) as well as a novel MTBC-selective mechanism of action (60). Like
pretomanid, bedaquiline targets energy metabolism. Bedaquiline binds ATP synthase
with high afﬁnity, interfering very efﬁciently with its activity (61). Because ATP synthesis
is an essential process in dormant cells, treatment of hypoxic nonreplicating bacilli with
bedaquiline reduces the cell count more dramatically than isoniazid (an inhibitor of
mycolic acid synthesis) (62). Recently, clinical trials with bedaquiline achieved promis-
ing results, and in 2016, it acquired prior-authorization status under the trade name
Sirturo.
Alternative Treatment Concepts
When cells enter dormancy, they become less vulnerable to most antibiotics, yet
they must resuscitate to cause the symptomatic disease. Therefore, the use of inter-
mittent drug dosing has been proposed as an alternative approach for killing dormant
cell populations. The theory behind this assumes that during the time in which no
drugs are given, cells resuscitate and become susceptible to drugs again. This was ﬁrst
proposed by the discoverer of dormant cells, J. Bigger (63), but despite working in vitro,
this approach has several complications in vivo (Table 2). The withdrawal of antibiotics
is not uniform in the body (64), and suboptimal dosing can stimulate the selection of
resistant cells. Thus, there is considerable debate about the intermittency of the
treatment. On the one hand, intermittent treatment with RIF, PZA, and EMB has an
TABLE 2 Approaches explored in order to optimize TB therapy
Method Pro(s) Con(s) References
Intermittent Shortens treatment, reduces dosage Emergence of resistance, requires supervision 65–68
High dose Reduces visits to clinicians, eradicates persisters Toxicity, tolerance 71, 72
Resuscitation Tackles persistent cells directly Uncontrolled resuscitation might cause relapse 73, 74
Immunotherapy adjuvants Promising approach, reduces toxicity Unexpected adverse reactions, variable success,
more studies required
75–78
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efﬁcacy similar to that of conventional treatment (65), and this will reduce the number
of visits to the doctor, which increases patient adherence to treatment. On the other
hand, intermittent treatment has been proven to cause intolerance (66), and clinical
studies showed adverse reactions to intermittent therapy with RIF (67). More impor-
tantly, there is a substantial risk of relapse with RIF resistance, mainly in HIV-infected
patients (68). Because of the insufﬁcient evidence to support the utility of the inter-
mittent administration of antibiotics, this approach is currently discouraged by the
WHO (69).
Despite the inconclusive results for intermittent treatment regimens, this research
line resulted in a new treatment approach based on the high-dose administration of
antibiotics (70). During the initial stages of infection, the number of persistent cells is
at a minimum; thus, a high dose of the antibiotic may eliminate a high number of cells
faster, and the few survivors can be eliminated by the immune system. Tests in mice
have indicated that a high-dose RIF regimen resulted in faster clearance (71). In
addition, an increased dose of RIF shortened the duration of TB treatment (72). Based
on these observations, another new phase II trial has been started, investigating the
tolerability and toxicity problems of high-dose RIF treatment (72).
Other approaches involve substances that stimulate resuscitation from dor-
mancy as coadjutants during conventional treatments. This hypothesis was ﬁrst
proposed by Seidi and Jahanban-Esfahlan (73), who suggested the delivery of
resuscitation-promoting factor (RPF) to awaken dormant cells in combination with
standard antibiotic treatment. After resuscitation, the cells should become suscep-
tible, and thus, the infection should be eradicated. Because puriﬁed RPF lost most
of its activity in vivo, Gan et al. proposed the use of mycobacterial phages to induce
RPF expression, combined with standard therapy (74). However, none of these
strategies have been tested in vivo yet.
Finally, host-directed therapy, which aims to stimulate the immune response to
improve clinical outcomes, has received increased attention. The concurrent adminis-
tration of adjuvants with antimicrobial chemotherapy has produced some positive
preliminary results. For example, supplementation of standard treatment with tumor
necrosis factor (TNF) blockers to reactivate latent MTBC infection has been to be found
practical in patients with life-threatening tuberculosis infection (75). In addition, sup-
plementation with high-dose corticosteroids to reduce TNF levels caused a striking
reduction in sputum production. However, the adverse effects of corticosteroids (in-
cluding hyperglycemia, hypertension, and ﬂuid retention) make the continuation of
studies with this therapy unlikely (76). Adjuvant therapy with IFN and interleukin-2
(IL-2) have been studied in only small numbers of clinical cases, so it is difﬁcult to
develop deﬁnitive conclusions (77, 78).
CONCLUSIONS
The success of the M. tuberculosis complex is largely attributable to its ability to
escape the host immune response and persist in the host. Therefore, drugs that are
rapidly bactericidal in vitro require prolonged administration to achieve comparable
effects in vivo. This is most likely due to reservoirs of dormant MTBC cells that
remain initially unaffected by the drugs and host immune system. A dormant state
seems to be a critical component of the MTBC life cycle and a frequent reason for
treatment failure or relapse, thus presenting an important challenge for improving
TB therapies.
The understanding of dormancy in MTBC cells remains incomplete, and further
studies are required. Current data indicate that dormancy is caused by cells in a
metabolic state (6, 9, 41). The reduced metabolic activity protects nongrowing cells
against antibiotic action and the immune system, providing the possibility that any
dormant cells can resuscitate if treatment is interrupted (8). The stringent response
represents a reliable model to describe how cells switch from growth to a quiescent
state (9), and TA modules might explain why, under optimal growth conditions, a
small proportion of dormant cells is always present, even in an exponentially
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growing population. Interestingly, there is an association between some MTBC
lineages and treatment failure as well as drug resistance; this may be related to
larger proportions of dormant cells in a patient infected with bacteria from these
lineages (79).
Overall, the pathway toward dormancy is complex. There is considerable evi-
dence for an interaction between the stringent response and the TA modules: the
ppGpp synthase interacts with the mazEF family toxins (80), VapBC also interacts
with mazEF modules (81), and poly-P enhances the activity of Clp and Lon pro-
teases, increasing the degradation of toxins (15), to give just a few examples. A
more complete, holistic understanding of the genetic network explicitly controlling
dormancy in MTBC strains is crucial for the determination of key targets for novel
antimycobacterial agents. Therapy that is active against both growing and non-
growing cells would be expected to shorten the duration of treatment.
Currently, few options are available for shortened treatment regimens, especially
in the case of MDR/XDR strains (3). The translation from a basic laboratory exper-
iment to clinical application is long and arduous. However, strategic alliances, such
as the TB Alliance, Stop TB (WHO), or the Aeras Global TB Vaccine Foundation, speed
up this process to close the gap between basic and further drug development,
including preclinical tests and phase I to III trials. New drugs such as cyclopeptides
have been explicitly designed to target dormant cells, with a very precise knowl-
edge of the molecular target. This is the result of a more profound comprehension
of the genetic cell network in conjunction with the development of in vitro models
with better concordance with in vivo conditions. Furthermore, gene-targeting
approaches offer an exciting perspective, such as few interactions with other drugs,
yet the associated genetic tools are still in a very early stage. Although their
application might not be possible soon, if successful, it would open a new horizon
in medicine.
Finally, the WHO Stop TB strategy aims to eliminate TB in 2050 (82). The latest WHO
model predicts that current technology could achieve a 20% annual reduction in the
incidence of TB. If just 8% of people infected with an MTBC strain were entirely and
permanently protected each year, the incidence would fall to 90 per million population
by 2050 (82). Therefore, an understanding of persistent MTBC infection represents a key
research priority.
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